NSZU Works on Further Expansion of Drug Reimbursement Program in October
The National Health Service of Ukraine (NSZU) is actively working on expanding its drug reimbursement program, which is scheduled for October this year, as announced by Deputy Head Oleksandr Ryabets during a press conference on Thursday.
The National Health Service of Ukraine (NSZU) is making significant strides towards the expansion of its drug reimbursement program, which is set to take place in October of this year. This announcement was made by Oleksandr Ryabets, the Deputy Head of NSZU responsible for digital development, digital transformation, and digitalization, during a press conference held on Thursday.
According to Ryabets, the drug reimbursement program in Ukraine began its journey in 2019, initially covering 21 international non-proprietary names (INN). As of today, he mentioned that by 2025, the program aims to include 100 INNs, with an increase to 122 INNs expected by 2026. This expansion will encompass more than 740 brand names of pharmaceutical products, significantly broadening the scope of the program.
Ryabets emphasized that the ongoing development of the drug reimbursement program is crucial for alleviating the financial burden of treatment for patients. Currently, the reimbursement process is being initiated for two INNs related to the treatment of type 2 diabetes. Simultaneously, NSZU is collaborating with the Ministry of Health of Ukraine (MOH) to further expand the “Affordable Medicines” program in October.
Furthermore, Ryabets pointed out that as part of this expansion, there is a consideration to include test strips for patients with type 2 diabetes in the program. Additionally, plans are underway to ensure free access to insulin for older patients, particularly those aged 65 and above. However, he noted that specific details regarding this new initiative are yet to be finalized.
These initiatives are part of NSZU's efforts to improve access to medical services and medications for Ukrainians, especially those suffering from chronic illnesses. It is important to highlight that the drug reimbursement program has become a vital step in ensuring the availability of medical products to the population, particularly in light of the current challenges faced in the healthcare sector.
In conclusion, Oleksandr Ryabets expressed hope that the new changes in the drug reimbursement program will significantly ease the lives of patients suffering from diabetes and contribute to the overall improvement of the health status of the Ukrainian population.